TrialClinical lung cancer2017

Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.

Natasha B Leighl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.